News
Menu
News Releases
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vancouver, Canada, January 5, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6, 2021 at 3:00pm Eastern Time.
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
Vancouver, Canada. December 15, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited (“Novotech”), a leading full-service contract research organization (“CRO”) in Asia-Pacific, for its upcoming Phase 1 clinical trial for NVG-291. NervGen currently plans to initiate its Phase 1 clinical trial in Australia starting in Q1 2021.
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, Canada. November 19, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020.
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer’s Disease Program
NervGen Renews Business Advisory Relationship with Brian McAlister
Vancouver, Canada. November 10, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio, to provide independent, expert and multi-disciplinary strategic advice to guide the development of the Company’s lead compound, NVG-291, in the treatment of Alzheimer’s disease. NervGen is also pleased to announce that Brian McAlister, NervGen co-founder, has agreed to extend his engagement as a strategic advisor with the Company for an additional two years.
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
Vancouver, Canada. October 28, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company’s Board of Directors. Separately, NervGen announced that they were advised by its clinical research organization of a logistical delay in obtaining certain materials that are necessary to complete the analysis of their ongoing non-clinical studies. The results of these studies are required prior to initiating the Phase 1 trial; therefore, the Company has revised its guidance for the start of its Phase 1 study from Q4 2020 to Q1 2021.
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-dilutive Funding Sources for NVG-291
Vancouver, Canada. October 19, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly Director of the U.S. Combat Casualty Care Research Program, to help NervGen identify, prioritize and secure sources of non-dilutive funding for developing its lead compound, NVG-291, for treating nerve damage.
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
Vancouver, Canada. October 1, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury and Alzheimer’s disease.
NervGen Pharma Announces Annual General Meeting and Company Update to be Held on September 30, 2020
Vancouver, Canada. September 22, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholders (the “AGM”) on Wednesday, September 30, 2020 at 2:00 p.m. PDT, as previously advised in the Company’s Notice of Meeting filed with the Canadian securities regulatory authorities and posted on SEDAR on September 2, 2020.
NervGen Pharma Announces Departure of Chief Operating Officer
LifeSci Advisors Engaged to Provide Investor Relations Services
Vancouver, Canada. September 10, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Lloyd Mackenzie has resigned from his position as Chief Operating Officer effective October 2, 2020 in order to assume the President position of a private company not related to the focus of NervGen. The Company also announced that it has engaged New York based LifeSci Advisors, LLC (“LifeSci”) to provide investor relations services.
NervGen Pharma Reports Second Quarter 2020 Results
Phase 1 Clinical Study Remains on Track for Q4 2020
Vancouver, Canada. August 21, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the second quarter ended June 30, 2020.
NervGen Pharma Corp. Completes $6.45 Million Public Offering
Vancouver, Canada. August 10, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that today it has closed its previously announced “best efforts” public offering of 3,685,714 units of the Company (“Units”) at a price of $1.75 per Unit for aggregate gross proceeds of $6,450,000 (the “Offering”). The Offering was led by Haywood Securities Inc. (“Haywood”) who acted as sole agent and bookrunner. Brookline Capital Markets, a division of Arcadia Securities LLC, was the lead United States placement agent, acting as a member of the selling group.
NervGen Pharma Corp. Announces Upsizing of Financing and Filing of Amended and Restated Prospectus Supplement
Vancouver, Canada. August 4, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that it has increased the size of its previously announced common share offering. The Company intends to issue up to 3,685,714 units of the Company (“Units”) at a price of $1.75 per Unit for aggregate gross proceeds of up to $6.45 million (the “Offering”). The Company has agreed with the Agents that the books are now closed and they are no longer soliciting new subscribers for this Offering.
NervGen Pharma Corp. Announces Filing of Prospectus Supplement
Vancouver, Canada. July 30, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announces that the Company has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated January 2, 2020 (the “Base Shelf Prospectus”) in connection with its previously announced ‘best efforts” public offering of up to 3,142,857 units of the Company (the “Units”) at a price of $1.75 per Unit for aggregate gross proceeds of up to $5,500,000 (the “Offering”).
NervGen Pharma Announces Pricing of Public Offering
Vancouver, Canada. July 27, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has priced its previously announced offering of equity securities (the “Offering”). Pursuant to the Offering, NervGen intends to issue units of the Company (the “Units”) at a price of $1.75 per Unit.
NervGen Pharma Corp. Announces Public Offering
Vancouver, Canada. July 22, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce a “best efforts” public offering (the “Offering”) of equity securities of the Company (“Securities”).
NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
Ohio Department of Higher Education Awards $250,000 Grant to Dr. Jerry Silver, Co-inventor of NervGen’s Lead Compound
Vancouver, Canada. June 22, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Dr. Jerry Silver of Case Western Reserve University (“CWRU”) in Cleveland, Ohio, has been awarded a research grant by the State of Ohio to conduct preclinical studies in spinal cord injury in collaboration with NervGen, including the effect of NVG-291 in a chronic setting. Dr. Silver is a renowned spinal cord injury and regenerative medicine researcher and Professor of Neurosciences at CWRU, as well as the co-inventor of NervGen’s lead compound, NVG-291.
NervGen Pharma Grants Stock Options
Vancouver, Canada. June 1, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the first quarter ended March 31, 2020.
NervGen Pharma Reports First Quarter 2020 Results
Phase 1 Clinical Trial Remains on Track for Q4 2020
Vancouver, Canada. June 1, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the first quarter ended March 31, 2020.
NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, Canada. May 20, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of 1,806,827 units of the Company at a price of CAD$1.25 per unit, for aggregate gross proceeds to the Company of CAD$2,258,534.
NervGen Pharma Reports 2019 Year End Results
Phase 1 Clinical Study Remains on Track for Q4 2020
Vancouver, Canada. April 29, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2019.
NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic
Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th
Phase 1 Clinical Study Remains on Track for Q4 2020
Vancouver, Canada. April 6, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided an update on its business in response to the COVID-19 global crisis.
NervGen Pharma Provides a Development Update on its Lead Product NVG-291
Vancouver, Canada. February 26, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage today is providing an update to its development plan for its lead program, NVG-291.
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
Vancouver, Canada. February 24, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of Chief Financial Officer effective immediately. Mr. Adams replaces Mr. Robert Pilz who will continue to formally support the Company as a consultant.
NervGen Pharma Responds To Recent Increase In Market Activity
Vancouver, Canada. January 13, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company’s management is unaware of any undisclosed information or material change in the Company’s operations that would account for the recent increase in market activity.
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer / Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer
Vancouver, Canada. November 27, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO effective immediately, replacing Dr. Ernest Wong who will continue to formally support the Company as a consultant. Mr. Brennan has also been appointed as a member of NervGen’s Board of Directors. The Company also announced the appointment of Mr. Lloyd Mackenzie in the newly created position of Chief Operating Officer, also effective immediately.
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
Vancouver, Canada. November 21, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has issued 1,500,000 common shares (the “Common Share(s)”) to its manufacturing partner, CSBio, as partial consideration for an order of NVG-291 that will be used in the Company’s clinical development programs (the “Transaction”). No proceeds were raised from the Transaction.
NervGen Receives Investment from Drug Manufacturing Partner / CSBio Invests US$1,500,000 As Part of Manufacturing Contract For Clinical Trial Product
Vancouver, Canada. November 18, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a price of US$1.00 (CA$1.3231 equivalent) per common share on a private placement basis for a deemed value of US$1,500,000 with its peptide manufacturing partner, CSBio of Menlo Park, California. The investment will be applied in its entirety as the initial deposit for the Company’s US$3,000,000 order from CSBio of NVG-291 that will be used in the clinical development programs scheduled to start in early 2020.
NervGen Pharma Expands Platform Into Alzheimer’s Disease / NervGen Pharma’s NVG-291 Compound on Track to Begin Phase 1 in Q1 2020
Vancouver, Canada. October 28, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to generate new treatments for Alzheimer’s disease (“AD”).
NervGen Pharma Announces Clinical Development Plan For the Treatment of Nerve Damage and Neurodegenerative Diseases / NervGen Reports Results of Annual General Meeting of Shareholders
Vancouver, Canada. September 6, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two lead indications: spinal cord injury and multiple sclerosis.
NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper
Vancouver, Canada. July 10, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen’s core Intracellular Sigma Peptide (“ISP”) technology in a mouse model representative of demyelination in multiple sclerosis.
NervGen Amends Investor Relations Agreement
Vancouver, Canada. July 5, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of an investor relations services agreement dated January 16, 2019 with Mr. Huitt Tracey of Vancouver, Canada.
NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination / Lead Indication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial
Vancouver, Canada. June 26, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond spinal cord injury to multiple sclerosis (“MS”), another debilitating nerve damage related condition impacting millions of patients worldwide.
NervGen Pharma Announces Upgrade to the OTCQX® Best Market in the U.S.
Vancouver, Canada. June 10, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares on the OTCQX® Best Market (“OTCQX”). NervGen upgraded to OTCQX from the OTCQB® Venture Market and begins trading today under the symbol “NGENF”.
NervGen Pharma Presenting at the 9th Annual LD Micro Invitational
Vancouver, Canada. June 4, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma’s President & CEO, will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5 at 8:40AM PDT / 11:40AM EDT. In addition, NervGen representatives will be available for investor meetings during the event.
NervGen Pharma Engages Torrey Hills Capital for Investor Relations
Vancouver, Canada. June 3, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San Diego based Torrey Hills Capital, Inc. (“Torrey Hills Capital”) to provide market awareness and investor relations services to the Company.
NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing / Paul Brennan Joins NervGen Pharma as Business Advisor
Vancouver, Canada. May 30, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, PhD, as the Company’s Vice President, Chemistry, Manufacturing and Control (CMC). In addition, Paul Brennan has joined the NervGen team to advise on strategy and business development.
NervGen Pharma Commences Trading on OTCQB / NervGen Pharma Engages Market Maker
Vancouver, Canada. May 3, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading on the TSX Venture Exchange, its common shares will commence trading today on the OTCQB Venture Market under the symbol “NGENF”.
NervGen Pharma to Ring the Opening Bell of Toronto Stock Exchange / NervGen Pharma Closes Private Placement
Vancouver, Canada. May 1, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that the Company will ring the opening bell at Toronto Stock Exchange tomorrow morning to celebrate its listing on March 13, 2019.
NervGen Pharma’s Patent Estate Grows with the Addition of US Patents for its Groundbreaking Nerve Regeneration Technology
Vancouver, B.C. April 24, 2019 NervGen Pharma Corp. (“NervGen”) (TSX.V: NGEN), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTP) targeted therapies for heart diseases and injury, and for root avulsion involving injuries into the peripheral nerve system.
NervGen Pharma Increases Private Placement to $740,000
Vancouver, Canada. April 23, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $740,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) and 300,000 shares at $1.30 each (new).
NervGen Pharma Appoints Amy Franke as VP, Clinical Operations
Vancouver, Canada. April 1, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Amy Franke as the Company’s Vice President, Clinical Operations.
NervGen Pharma Announces $500,00 Private Placement
Vancouver, Canada. March 14, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it intends to complete a non-brokered private placement raising up to $500,000 through the issuance of up to 500,000 shares at $1.00 each.
NervGen Pharma Completes $10 Million Initial Public Offering / Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
Vancouver, Canada. March 13, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering (“IPO”) of its common shares and listing as a Tier 2 company on the TSX Venture Exchange (“TSX-V”).
NervGen Pharma Appoints Dr. Michael Abrams to Board of Directors
Vancouver, Canada. September 25, 2018 – NervGen Pharma Corp. (“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Dr. Michael J. Abrams, PhD, to the Company’s Board of Directors.
NervGen Announces Granting of US Patent for Breakthrough Nerve Regeneration Technology
Vancouver, B.C. August 10, 2018 NervGen Pharma Corp. (“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of a patent central to the development and commercialization of protein tyrosine phosphatase sigma (PTPsigma) targeted therapies for spinal cord injury and nerve damage.
NervGen Licenses Breakthrough Nerve Regeneration Technology from Case Western Reserve University
July 17, 2018—NervGen Pharma Corp. (“NervGen”), in Vancouver, and Case Western Reserve University (“Case Western Reserve”) in Cleveland have entered into an exclusive worldwide licensing agreement to research, develop and commercialize a patented technology with potential to bring new therapies for spinal cord injury and other conditions associated with nerve damage.
NervGen Appoints Dr. Ernest Wong as President & CEO
Experienced Biotechnology Executive to Lead Innovative Regenerative Medicine Company Dedicated to Creating Solutions for the Treatment of Nerve Damage
Vancouver, Canada. June 21, 2018 – NervGen Pharma Corp. (“NervGen”), a private regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of spinal cord injury and nerve damage, today announced the appointment of Ernest Wong, PhD MBA, as President & Chief Executive Officer.
Articles
NervGen CFO: Dig Into Strategy
StrategicCFO360
November 9, 2020
StrategicCFO360 interviews Bill Adams about about how he manages a broadening role in a small, but fast growing biotech.
Industry Matters: NervGen Targets Glial Scars to Treat Alzheimer’s
Scientific Inquirer
November 5, 2020
Scientific Inquirer interviews Paul Brennan about the company’s technology and bright future.
Releasing the Handbrake on Endogenous Repair – An Alternate Approach to Treating Alzheimer’s Disease
Technology Networks
January 13, 2020
Technology Networks speaks with Paul Brennan to gain his insights on previous attempts to treat Alzheimer’s disease, how NVG-291 works, and what promise it hold for Alzheimer’s disease.
Emerging Treatments for Spinal Cord Damage
Asia-Pacific Biotech News
August 27, 2019
Can damaged nerves regenerate?
A Real Growing Concern
Laboratory News
June 1, 2019
Dr. Jerry Silver, Professor of Neurosciences at Case Western University, discusses emerging treatments for spinal cord injury.
Injectable Peptide Might Help Spinal Cord Injury Patients Walk Again
BioSpace
May 19, 2019
Summarizes how NervGen’s technology may make it possible to restore lost functions in spinal cord injury patients, moving toward clinical trials in early 2020.
Spinal Cord Damage and Emerging Treatments
Scientia
February 5, 2019
Dr Silver and his team at Case Western University have teamed up with NervGen Pharma, whose vision is to restore life’s potential to patients by creating innovative solutions for the treatment of nerve damage. Together, they have identified an ISP analogue known as NVG-291 to treat human patients. It is their hope that this technology can improve the lives for the many people living with debilitating nerve damage.
“Inhibiting the Inhibitors” to Support Axonal Regeneration
Neurosurgery
February 1, 2016
After spinal cord injury (SCI), the disruptive interactions of chondroitin sulfate proteoglycans (CSPGs) produced by reactive astrocytes create glial scars that are major barriers to neural circuit reconnection and functional recovery. Recent work reveals a novel strategy to inhibit an inhibitor of neural regeneration.
OHSU Researchers Discover Peptide That Can Penetrate Heart Attack Scar Tissue, Regenerate Cardiac Nerves
Cardiovascular Disease News
February 3, 2015
Results from a recent study conducted by a team of researchers at the Oregon Health & Sciences University (OHSU), indicate that a specific peptide named ISP can penetrate heart attack scar tissue and restore cardiac nerves.
Rats with Spinal Cord Injury Regain Bladder Function and Some Mobility Following Injection with Novel Drug
Neurology Today
January 22, 2015
Researchers reported that in rats with spinal cord injury, systemic delivery of a novel drug facilitated functional recovery of locomotor and urinary systems.
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
Science of Singularity
December 7, 2014
Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.
The results demonstrate how fundamental laboratory research may lead to new therapies. “We’re very excited at the possibility that millions of people could, one day, regain movements lost during spinal cord injuries,” said Jerry Silver, Ph.D.
Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.
Peptide Helps Paralyzed Rats Recover Function
RedOrbit
December 6, 2014
Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.
Intracellular Sigma Peptide: Breakthrough Drug May Heal Damaged Spines
AskMen
December 4, 2014
For the first time, scientists may have found a drug that can help heal a damaged spine and restore some movement and bladder control.Study researchers found that ISP helped lab rats with spinal cord injuries regain the ability to control urination, move or both. They added that the results could be a sign the compound could be used in the future for treating humans with similar injuries.
Drug Found to Help Repair Spinal Cord Injuries
NHS Choices
December 4, 2014
“Renewed hope for patients paralysed by spine injuries,” The Independent reports. This hope is due to the possibility of developing a new drug based on a molecule called intracellular sigma peptide. The drug helped restore varying degrees of nerve functions in rats that had spinal cord injuries.
Peptide Shows Great Promise for Treating Spinal Cord Injury
Spinal Cord Injury Zone
December 3, 2014
Case Western Reserve scientists design intracellular sigma peptide (ISP) to promote functional recovery following spinal cord injury.
Media
BioPub Presents: Maximizing Value, NervGen’s Indication Strategy and Operational Update
BioPub
December 16, 2020
BioPub webcast with Paul Brennan.
Finding Genius Podcast
Finding Genius Podcast
November 3, 2020
Finding Genius Podcast with Paul Brennan.
BioPub Presents NervGen: An Intro to the New Management
BioPub
March 11, 2020
BioPub webcast with NervGen’s recently appointed leadership team.
Unite 2 Fight Paralysis CureCast with NervGen Pharma
Unite 2 Fight Paralysis
April 22, 2020
Unite 2 Fight Paralysis podcast with Dr. Harold Punnett and Paul Brennan.
BioPub in Conversation with NervGen Pharma
BioPub
October 31, 2019
BioPub webcast with Dr. Jerry Silver, Dr. Harold Punnett and Dr. Ernest Wong. Dr. Marc DePaul joins to present NervGen’s technology.
Jerry Silver on HealthPro Radio
HealthPro Radio
September 24, 2019
Dr. Jerry Silver’s interview by Health Professional Radio, an internet-only media network.
Harold Punnett on the Price of Business Show
Price of Business
August 22, 2019
Dr. Harold Punnett’s interview on The Price of Business, a nationally syndicated show on USA Business Radio.
OTC Virtual Investor Conference Webcast
OTC
July 11, 2019
Dr. Ernest Wong presented at OTC’s Virtual Investor Conference on July 11, 2019 at 10:30a.m. ET.
BioPub Webcast about NervGen Pharma
BioPub
May 10, 2019
BioPub webcast with Dr. Ernest Wong, CEO of NervGen, and Dr. Jerry Silver, Co-Inventor and Scientific Advisor of NervGen.
Jerry Silver on the Price of Business Show
Price of Business
March 4, 2019
Kevin Price interviews Dr. Jerry Silver on The Price of Business, a nationally syndicated show on USA Business Radio.
